Craneware (LON:CRW) Hits New 52-Week High at $2,300.00

Craneware plc (LON:CRW)’s stock price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 2,300 ($28.89) and last traded at GBX 2,275 ($28.58), with a volume of 60642 shares changing hands. The stock had previously closed at GBX 2,240 ($28.14).

Analyst Ratings Changes

Separately, Berenberg Bank raised their target price on shares of Craneware from GBX 2,300 ($28.89) to GBX 2,600 ($32.66) and gave the company a “buy” rating in a research note on Monday, March 4th.

Craneware Stock Up 0.9 %

The company has a debt-to-equity ratio of 19.15, a quick ratio of 1.00 and a current ratio of 0.78. The company has a market capitalization of £812.59 million, a price-to-earnings ratio of 10,952.38 and a beta of 0.13. The firm’s 50-day simple moving average is GBX 2,188.07 and its 200-day simple moving average is GBX 1,933.19.

Craneware Cuts Dividend

The business also recently declared a dividend, which was paid on Monday, April 15th. Shareholders of record on Thursday, March 21st were given a GBX 13 ($0.16) dividend. The ex-dividend date of this dividend was Thursday, March 21st. This represents a yield of 0.62%. Craneware’s dividend payout ratio is 13,809.52%.

Craneware Company Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Trisus pricing transparency software; Trisus Pricing Analyzer, a solution that simplifies and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity for the United States payors; Trisus Claims Informatics, a retrospective charge capture analytical application that identifies areas of risk for its team to investigate; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit management solution for government and commercial payors.